carnosine has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aita, H; Chaki, K; Hori, Y; Morita, H; Seiki, M; Tagashira, E; Takemasa, T; Ueki, S; Yoneta, T | 1 |
| Choi, YH; Hwang, B; Kim, WJ; Moon, SK; Shin, SS; Song, JH | 1 |
2 other study(ies) available for carnosine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
[Effect of Z-103 on wound healing by dermal incision in guinea pigs].
Topics: Animals; Anti-Ulcer Agents; Carnosine; Dipeptides; Disease Models, Animal; Guinea Pigs; Hydroxyproline; Male; Neovascularization, Pathologic; Organometallic Compounds; Skin; Tensile Strength; Wound Healing; Zinc Compounds | 1992 |
Carnosine exerts antitumor activity against bladder cancers in vitro and in vivo via suppression of angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Carnosine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Nitric Oxide Synthase Type III; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2019 |